Research statistics
Anamorelin research: publications and trials
At a glance
Publications, all years
146
Since 2007
Publications in 2026 so far
18
Through November 15, 2026
Human clinical research
47.3%
69 of 146 classified
Registered clinical trials
14
ClinicalTrials.gov
Randomized controlled trials
16
Publications reporting an RCT in people
Systematic reviews and meta-analyses
7
Preclinical studies
15.8%
13 animal · 9 in vitro · 1 computational
Records that only mention it
32
Not counted above
Status in the library: In clinical trials. Groups: Growth hormone axis.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
- Not a peptide: it is shown for completeness and left out of every peptide total.
Publications by year
Anamorelin publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2007 | 1 | 0 | 0 | 0 | 1 |
| 2009 | 1 | 0 | 0 | 0 | 1 |
| 2011 | 0 | 1 | 0 | 0 | 1 |
| 2012 | 1 | 0 | 0 | 0 | 1 |
| 2013 | 0 | 1 | 0 | 0 | 1 |
| 2014 | 2 | 1 | 1 | 1 | 5 |
| 2015 | 1 | 1 | 3 | 1 | 6 |
| 2016 | 2 | 0 | 2 | 0 | 4 |
| 2017 | 3 | 0 | 7 | 2 | 12 |
| 2018 | 0 | 0 | 7 | 0 | 7 |
| 2019 | 2 | 0 | 2 | 0 | 4 |
| 2020 | 0 | 3 | 1 | 2 | 6 |
| 2021 | 1 | 0 | 5 | 0 | 6 |
| 2022 | 7 | 2 | 1 | 1 | 11 |
| 2023 | 4 | 2 | 4 | 3 | 13 |
| 2024 | 16 | 5 | 4 | 2 | 27 |
| 2025 | 15 | 3 | 3 | 1 | 22 |
| 2026 (to date) | 13 | 4 | 0 | 1 | 18 |
Study types
| Observational human study | 37 |
|---|---|
| Review | 33 |
| Randomized controlled trial | 16 |
| Editorial, letter or other | 14 |
| Animal study | 13 |
| Case report | 10 |
| In vitro study | 9 |
| Other clinical trial | 6 |
| Meta-analysis | 5 |
| Systematic review | 2 |
| Computational study | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Oncology | 109 |
|---|---|
| Obesity and weight management | 90 |
| Gastrointestinal | 25 |
| Endocrinology | 18 |
| Metabolic health | 18 |
| Musculoskeletal | 8 |
| Cardiovascular | 7 |
| Neurological and mental health | 7 |
| Immune system | 3 |
| Cognitive health | 1 |
Registered clinical trials
2 of 10 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 10 · Active, not recruiting: 2 · Terminated: 2
Phase 1: 1 · Phase 2: 7 · Phase 2 / Phase 3: 1 · Phase 3: 5
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis.
Scientific reports · September 14, 2023 · Meta-analysis · cited 34 times · open access
PMID 37709824 · DOI 10.1038/s41598-023-42446-x · Reviews and meta-analyses
- The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · August 1, 2023 · Meta-analysis · cited 12 times
PMID 37525932 · DOI 10.1177/10781552231189864 · Reviews and meta-analyses
- The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews.
BMC complementary and alternative medicine · August 9, 2018 · Meta-analysis · cited 42 times · open access
PMID 30092794 · DOI 10.1186/s12906-018-2304-8 · Reviews and meta-analyses
- Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
Lung cancer (Amsterdam, Netherlands) · July 27, 2017 · Meta-analysis · cited 52 times
PMID 29191597 · DOI 10.1016/j.lungcan.2017.07.023 · Reviews and meta-analyses
- Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · January 10, 2017 · Meta-analysis · cited 52 times
PMID 28074289 · DOI 10.1007/s00520-016-3560-0 · Reviews and meta-analyses
- Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta-analysis.
Cancer medicine · September 1, 2024 · Systematic review · cited 15 times · open access
PMID 39225556 · DOI 10.1002/cam4.70166 · Reviews and meta-analyses
- Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.
BMC cancer · November 27, 2018 · Systematic review · cited 118 times · open access
PMID 30482179 · DOI 10.1186/s12885-018-5080-4 · Reviews and meta-analyses
- Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.
EClinicalMedicine · September 22, 2025 · Randomized controlled trial · cited 5 times · open access
PMID 41181834 · DOI 10.1016/j.eclinm.2025.103500 · Human clinical research
- Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study.
The oncologist · July 1, 2025 · Randomized controlled trial · cited 1 times · open access
PMID 40592718 · DOI 10.1093/oncolo/oyaf167 · Human clinical research
- Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.
Journal of cachexia, sarcopenia and muscle · February 1, 2025 · Randomized controlled trial · cited 22 times · open access
PMID 39992021 · DOI 10.1002/jcsm.13732 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
The Lancet. Oncology · February 20, 2016 · Randomized controlled trial · cited 640 times · open access
PMID 26906526 · DOI 10.1016/s1470-2045(15)00558-6 · Human clinical research
- Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Cancer · December 4, 2017 · Randomized controlled trial · cited 240 times · open access
PMID 29205286 · DOI 10.1002/cncr.31128 · Human clinical research
- Cancer Cachexia: Its Mechanism and Clinical Significance.
International journal of molecular sciences · August 6, 2021 · Review · cited 234 times · open access
PMID 34445197 · DOI 10.3390/ijms22168491 · Reviews and meta-analyses
- Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
The Lancet. Oncology · December 16, 2014 · Randomized controlled trial · cited 218 times
PMID 25524795 · DOI 10.1016/s1470-2045(14)71154-4 · Human clinical research
- ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.
Annals of oncology : official journal of the European Society for Medical Oncology · August 1, 2017 · Other clinical trial · cited 179 times · open access
PMID 28472437 · DOI 10.1093/annonc/mdx192 · Human clinical research
Latest publications
- Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study.
International journal of clinical pharmacology and therapeutics · November 1, 2026 · Observational human study · cited 0 times
PMID 42596744 · DOI 10.5414/cp204974 · Human clinical research
- Predictors of early discontinuation and therapeutic response to anamorelin in patients with cancer cachexia: A retrospective study.
International journal of clinical pharmacology and therapeutics · October 1, 2026 · Observational human study · cited 0 times
PMID 42544527 · DOI 10.5414/cp204997 · Human clinical research
- Exploring Inhibitory Impacts of Anamorelin on Colorectal Cancer Proliferation via Regulation of Transketolase.
Current medicinal chemistry · August 22, 2026 · In vitro study · cited 0 times
PMID 42693844 · DOI 10.2174/0109298673450549260810115103 · In vitro studies
- Predictors of 12-Week Anamorelin Treatment Continuation in Gastrointestinal Cancer Cachexia: A Single-Center, Retrospective Study.
Nutrition and cancer · August 11, 2026 · Observational human study · cited 0 times
PMID 42578447 · DOI 10.1080/01635581.2026.2713785 · Human clinical research
- A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).
Journal of cachexia, sarcopenia and muscle · August 1, 2026 · Observational human study · cited 0 times · open access
PMID 42411631 · DOI 10.1002/jcsm.70340 · Human clinical research
- Gamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia.
Internal medicine (Tokyo, Japan) · July 25, 2026 · Observational human study · cited 0 times · open access
PMID 42528246 · DOI 10.2169/internalmedicine.7787-26 · Human clinical research
- Trends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation.
Annals of nutrition & metabolism · June 26, 2026 · Observational human study · cited 0 times · open access
PMID 42360910 · DOI 10.1159/000553255 · Human clinical research
- Association between anamorelin therapy and renal function in patients with cancer cachexia: a propensity score-matched retrospective study.
European journal of clinical pharmacology · June 16, 2026 · Observational human study · cited 0 times
PMID 42298206 · DOI 10.1007/s00228-026-04110-x · Human clinical research
- Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan.
Value in health regional issues · June 4, 2026 · Computational study · cited 0 times · open access
PMID 42240544 · DOI 10.1016/j.vhri.2026.101653 · Computational studies
- Three-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic Nutritional Index.
Journal of palliative medicine · June 3, 2026 · Observational human study · cited 0 times
PMID 42237597 · DOI 10.1177/10966218261457190 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Adlumiz; Anamorelin; ONO-7643; RC-1291
((TITLE_ABS:"Adlumiz" OR CHEM:"Adlumiz") OR (TITLE_ABS:"Anamorelin" OR CHEM:"Anamorelin") OR (TITLE_ABS:"ONO-7643" OR CHEM:"ONO-7643" OR TITLE_ABS:"ONO7643" OR CHEM:"ONO7643") OR (TITLE_ABS:"RC-1291" OR CHEM:"RC-1291" OR TITLE_ABS:"RC1291" OR CHEM:"RC1291")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Anamorelin research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/anamorelin